What is the recommended dosing for Vyvanse (lisdexamfetamine) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vyvanse (Lisdexamfetamine) Dosing for Adults

For adults with ADHD, start lisdexamfetamine at 30 mg once daily in the morning, then titrate in 10-20 mg increments at weekly intervals to a maximum of 70 mg daily. 1

Standard Dosing Protocol

  • Starting dose: 30 mg once daily in the morning 1, 2
  • Titration schedule: Increase by 10 mg or 20 mg increments at approximately weekly intervals 1
  • Maximum recommended dose: 70 mg once daily 1, 2, 3
  • Timing: Take in the morning with or without food; avoid afternoon doses due to insomnia risk 1

Administration Options

Lisdexamfetamine can be administered in two ways 1:

  • Swallow capsule whole, or
  • Open capsule and mix entire contents with yogurt, water, or orange juice. Use a spoon to break apart any compacted powder. Consume the entire mixture immediately—do not store. 1

Critical pitfall: Do not divide a single dose. Always take at least one full capsule per day. 1

Dosing for Binge Eating Disorder (Adults)

For moderate to severe binge eating disorder 1, 4:

  • Starting dose: 30 mg once daily
  • Titration: Increase by 20 mg at weekly intervals
  • Target dose: 50-70 mg once daily
  • Maximum dose: 70 mg once daily
  • Discontinue if no improvement in binge eating occurs 1

Renal Impairment Adjustments

Dose reductions are mandatory in renal dysfunction 1:

  • Severe renal impairment (GFR 15 to <30 mL/min/1.73 m²): Maximum 50 mg once daily
  • End-stage renal disease (GFR <15 mL/min/1.73 m²): Maximum 30 mg once daily

Duration of Effect

Lisdexamfetamine provides extended symptom control 2, 3, 5:

  • Adults: Efficacy demonstrated at 14 hours post-dose 2
  • Children: Efficacy through 6 PM based on parent ratings 3
  • This extended duration results from the prodrug's rate-limited enzymatic conversion to active d-amphetamine in red blood cells 6, 5

Drug Interactions Requiring Dose Adjustment

Urinary pH-altering agents significantly impact amphetamine blood levels 1:

  • Acidifying agents (e.g., ascorbic acid): Decrease blood levels—may need to increase lisdexamfetamine dose
  • Alkalinizing agents (e.g., sodium bicarbonate): Increase blood levels—may need to decrease lisdexamfetamine dose

Absolute contraindication: Do not use within 14 days of MAOIs (including linezolid or IV methylene blue) due to hypertensive crisis risk 1

Common Pitfalls to Avoid

  • Never exceed 70 mg daily even if response is inadequate—instead, reassess diagnosis or switch to alternative medications 1
  • Do not crush or open extended-release formulations of other amphetamines, though lisdexamfetamine capsules can be opened and mixed as described above 1
  • Avoid late-day dosing to prevent insomnia 1
  • Do not use for weight loss—lisdexamfetamine is not indicated for obesity, and sympathomimetic drugs for weight loss have been associated with serious cardiovascular events 1

Monitoring Requirements

While not explicitly detailed in the FDA label, the American Academy of Child and Adolescent Psychiatry recommends 7:

  • Blood pressure and pulse: Check quarterly in adults on stimulants
  • Efficacy assessment: Use standardized ADHD rating scales when possible

Tolerability Profile

The most common adverse events in clinical trials were 4, 3, 6:

  • Dry mouth
  • Headache
  • Insomnia
  • Decreased appetite
  • Upper abdominal pain
  • Irritability
  • Weight loss
  • Nausea

Most adverse events were mild to moderate in intensity and transient 3, 5. Treatment discontinuation due to adverse events was infrequent 4.

Abuse Potential Considerations

Lisdexamfetamine was specifically designed as a prodrug to reduce abuse potential 1, 6:

  • Human abuse liability studies showed lower drug-liking scores compared with immediate-release d-amphetamine at equivalent doses 3
  • The prodrug remains therapeutically inactive until enzymatically converted to d-amphetamine, primarily in red blood cells 6, 5
  • This rate-limited conversion provides consistent plasma concentrations throughout the day 5

Warning: Misuse and abuse can still result in overdose and death, particularly with higher doses or unapproved administration methods (snorting, injection) 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.